Astellas Pharma, Inc. relies heavily on Xtandi (enzalutamide), the prostate cancer drug it commercializes in the US with Pfizer Inc. and the company's top revenue generator. While Xtandi still has growth potential ahead of its US loss of exclusivity, expected in 2027, Astellas is looking to bring a new generation of growth drivers to market in the US, starting with fezolinetant in women's health later this year.
Astellas Plots US Portfolio Expansion
US president Mark Reisenauer talked to Scrip about the company's next growth drivers, including fezolinetant for vasomotor symptoms and zolbetuximab for gastric cancer.
More from Strategy
More from Business
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.
• By
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.